The clinical use of plasma clozapine levels

Australian and New Zealand Journal of Psychiatry

Volumn 32, Issue 4, 1998, Pages 567-574

  Bell, Ron ^a   McLaren, Andrew ^a   Galanos, Jason ^a   Copolov, David ^a  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Clinical response; Clozapine; Plasma level

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CIMETIDINE; CLOZAPINE; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; NEUROLEPTIC AGENT; PENICILLIN G; PHENYTOIN; TETRACYCLINE;

AGRANULOCYTOSIS; ARTICLE; BLOOD SAMPLING; CLINICAL PRACTICE; CONSTIPATION; DIAPHORESIS; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RESPONSE; ENURESIS; FATIGUE; FEVER; HUMAN; HYPERSALIVATION; HYPOTENSION; LEUKOCYTOSIS; LEUKOPENIA; MEDICAL LITERATURE; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PROBABILITY; SCHIZOPHRENIA; SEIZURE; SKIN MANIFESTATION; TACHYCARDIA; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

EID: 0031872240     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.3109/00048679809068332     Document Type: Article

References (54)

1. Kane J, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988; 45:789-796.
2. Copolov DL, Bell WR, Benson WJ, Keks NA, Strazzeri DC, Johnson GF. Clozapine treatment in Australia-a review of haematological monitoring. Medical Journal of Australia 1997; 168:495-497.
3. Gelenberg AJ. Clozapine-induced agranulocytosis and seizures. Biology of Therapeutic Psychiatry 1989; 12:2-3.
4. Ackenheil V, Bräu H, Burkhan A, Franke A, Pacha W. Antipsychotische Wirksamkeit im Verhälms zum Plasmaspiegel von Clozapin (Antipsychotic efficacy in relation to plasma levels of ciozapine). Arzneimittelforschung 1976; 26:1156-1158.
5. Thorup M, Fog R. Clozapine treatment of schizophrenic patients: plasma concentrations and coagulation factors. Acta Psychiatrica Scandinavica 1977, 55:123-126.
6. Brau H, Burkhart A, Pacha W, Ackenheil V. Benziehungen zwischen Wirkungen und Plasmaspiegel von Clozapin (Relationships between effects and plasma levels of clozapine). Arzneimittelforschung 1978; 28:1300
7. Perry PJ, Miller DD, Arndt SV, Cadoret, RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. American Journal of Psychiatry 1991; 148:231-235.
8. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. Journal of Clinical Psychopharmacology 1993; 13:383-390.
9. Potkin SG, Bera R, Gulasekaram B et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. Journal of Clinical Psychiatry 1994; 55(Suppl. B) 133-136.
10. Miller DD, Fleming F, Holman TL, Perry PJ. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. Journal of Clinical Psychiatry 1994; 55(Suppl B):117-121.
11. Kronig MH, Munne RA, Szymanski S et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. American Journal of Psychiatry 1995; 152 179-182.
12. VanderZwaag C, McGee M, McEvoy JP et al. Response of patients with treatment-refractory schizophrenia to clozapine within three plasma level ranges. American Journal of Psychiatry 1996; 153:1579-1584.
13. Pirmohamed M, Williams D, Madden S, Templeton E, Park BK Metabolism and bioactivation of clozapine by human liver in vitro. Journal of Pharmacology and Experimental Therapeutics 1995; 272:984-990.
14. Rosenthal J, Nimmerfall F, Sigrist R et al. Non-equilibrium method for the radioimmuno-assay of clozapine in the presence of metabolites. European Journal of Biochemistry 1977; 80:603-609.
15. Fisher V, Vogels B, Maurer G et al The antipsychotic clozapine is metabolised by the polymorphic human microsomal and recombinant cytochrome P450 2D6. Journal of Pharmacology and Experimental Therapeutics 1992; 260:1355-1360.
16. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Therapeutic Drug Monitoring 1994; 16:368-374.
17. Haring C, Meise U, Humpel C et al. Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology 1989; 99:S38-40.
18. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. New England Journal of Medicine 1991; 324:746-54.
19. Haring C, Fleischhacker WW, Sehett P, Humpel C et al. Influence of patient-related variables on clozapine plasma levels American Journal of Psychiatry 1990; 147:1471-1475.
20. Oyewumi LK, Freeman DJ, Vollick D. Can low-dose clozapine pharmacokinetics predict steady-state plasma concentration? Therapeutic Drug Monitoring 1995; 17:137-141.
21. Centorrino F, Baldessarini RJ, Kando JC et al. Clozapine and metabolites. concentrations in plasma and clinical findings during treatment of chronically psychotic patients. Journal of Clinical Psychopharmacology 1994; 14:119-125.
22. Chung M-C, Lin S-K, Chang W-H. Determination of clozapine and desmethylclozapine in human plasma by high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography 1993; 613:168-173.
23. Centorrino F, Baldessarini RJ, Kando J et al. Plasma concentrations of clozapine and its major metabolites effects of co-treatment with fluoxetine or valproate. American Journal of Psychiatry 1994; 151:123-125.
24. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. Journal of Clinical Psychiatry 1996; 57:12-35.
25. Csik V, Molnar J. Possible adverse interaction between clozapine and ampicillin in an adolescent with schizophrenia. Journal of Child and Adolescent Psychopharmacology 1994; 4:123-128.
26. Jackson CW, Markowitz JS, Brewerton TD. Delirium associated with clozapine and benzodiazepine combinations. Annals of Clinical Psychiatry 1995; 7:139-141.
27. Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. Journal of Clinical Psychiatry 1991; 52:23-25.
28. Raitasuo V, Lehtovaara R, Huttunen MO. Carbamazepine and plasma levels of clozapine. American Journal of Psychiatry 1993; 150:169.
29. Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of antipsychotic drugs. Pharmopsychiatry 1995; 28:26-28.
30. Bachmann KA, Jauregui L. Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo. Xenobiotica 1993; 23:307-315.
31. Jones CR, Lubet RA. Induction of a pleiotropic response by phenobarbital and related compounds. Response in various inbred strains of rats, response in various species and the induction of aldehyde dehydrogenase in Copenhagen rats Biochemical Pharmacology 1992; 44:1651-1660.
32. Funderburg LG, Vertrees JE, True JE, Miller AL et al. Seizure after the addition of erythromycin to clozapine treatment. American Journal of Psychiatry 1994, 151:1840-1841.
33. Szymanski S, Lieberman JA, Picou D et al. A case report of cimetidine-induced clozapine toxicity Journal of Clinical Psychiatry 1991; 52:21-22.
34. Sesardic D, Boobis AR, Edwards RJ, Davies DS. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. British Journal of Clinical Pharmacology 1988; 26:363-372.
35. Yonkers KA, Kando JC, Cole JO, Blumenthal S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medications. American Journal of Psychiatry 1992; 149:587-595
36. Bondesson V, Lindstrom LH. Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. Psychopharmacology 1988; 95:471-475.
37. Jann MW, Grimsley SR, Gray EC, Chang WH. Pharmacokinetics and pharmacodynamics of clozapine. Clinical Pharmacokinetics 1993; 24; 161-176.
38. Atkin K, Kendall F, Gould D et al. Neutropenia and agranulocytosis in patients receiving clozapine in the UK, Ireland. British Journal of Psychiatry 1996; 169:483-488.
39. Alvir J, Ma J, Lieberman AJ, Safferman AZ et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. New England Journal of Medicine 1993; 329:162-167.
40. Haller E, Binder RL. Clozapine and seizures. American Journal of Psychiatry 1990; 147:1069-1071.
41. Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatric Quarterly 1992; 63:51-70
42. Naber D, Holzbach R, Perro C, Hippius H. Clinical management of clozapine patients in relation to efficacy and side-effects. British Journal of Psychiatry 1992; 160:54-59.
43. Thornberg SA, Ereshefsky L. Neuroleptic malignancy syndrome associated with clozapine monotherapy. Neuropharmacology 1993; 13:510-514
44. Chatterton R, Cardy S, Schramm TM. Neuroleptic malignant syndrome and clozapine monotherapy. Australian and New Zealand Journal of Psychiatry 1996; 30:692-693.
45. Lovdahl MJ, Perry PJ, Miller DD. The assay of clozapine and N-desmethylclozapine in human plasma by high-performance liquid chromatography. Therapeutic Drug Monitoring 1991; 13:69-72
46. Weigmann H, Hiemke C. Determination of clozapine and its major metabolites in human plasma using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography 1992; 583:209-216.
47. Freudenreich O, McEvoy JP, Cooper TB. Monitoring of clozapine blood levels in the real world. Journal of Clinical Psychopharmacology 1996; 16:90-91.
48. Lieberman JA, Kane JM, Safferman AZ et al Predictors of response to clozapine. Journal of Clinical Psychiatry 1994; 55:126-128.
49. Pickar D, Owen RR, Litman RE et al. Predictors of clozapine response in schizophrenia. Journal of Clinical Psychiatry 1994; 55:129-132.
50. Miller D. The clinical use of clozapine plasma concentrations in the management of treatment-refractory schizophrenia. Annals of Clinical Psychiatry 1996; 8:99-109.
51. Owen JA, Delva NJ; Lawson JS. Clozapine concentrations and clinical response in schizophrenic patients American Journal of Psychiatry 1992; 149:1120-1121
52. Perry J, Miller D. Clinical use of clozapine plasma concentrations. In Marder S, Davis JM, Janicak PG, eds. Clinical use of antipsychotic drug plasma levels. Washington, DC: American Psychiatric Press, 1993:85-99.
53. Gerson S, Arce C, Meltzer H N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. British Journal of Haematology 1994; 86:555-561
54. Nordin C, Alme B, Bondesson U. CSF and plasma concentrations of clozapine and its demethyl metabolite: a pilot study Psychopharmacology Berlin 1995; 122:104-107.